The specter of generic challenges has repeatedly loomed above copyright’s blockbuster drug, Viagra, sparking questions about the outlook of connected drug portfolios. While first years saw impressive returns, the intellectual property end has created the door for cheaper substitutes, possibly lowering profitability and creating a significant dang